Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Kana, Hara, Munechika, Iwakami, Shin-ichiro, Genda, Takuya, Iwakami, Naoko, Miyashita, Yosuke, Fujioka, Masahiro, Sasaki, Shinichi, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911765/
https://www.ncbi.nlm.nih.gov/pubmed/31735738
http://dx.doi.org/10.2169/internalmedicine.2591-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911765/
https://www.ncbi.nlm.nih.gov/pubmed/31735738
http://dx.doi.org/10.2169/internalmedicine.2591-18

Ejemplares similares